ADVFN Logo

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Registration Strip Icon for charts Register for streaming realtime charts, analysis tools, and prices.

DXRX Diaceutics Plc

96.00
-1.00 (-1.03%)
28 Feb 2024 - Closed
Delayed by 15 minutes
Share Name Share Symbol Market Type Share ISIN Share Description
Diaceutics Plc LSE:DXRX London Ordinary Share GB00BJQTGV64 ORD GBP0.002
  Price Change % Change Share Price Shares Traded Last Trade
  -1.00 -1.03% 96.00 22,301 08:33:55
Bid Price Offer Price High Price Low Price Open Price
95.00 97.00 96.50 96.00 96.50
Industry Sector Turnover Profit EPS - Basic PE Ratio Market Cap
Testing Laboratories 19.5M 724k 0.0086 111.63 81.09M
Last Trade Time Trade Type Trade Size Trade Price Currency
16:14:44 O 22 95.9999 GBX

Diaceutics (DXRX) Latest News

Diaceutics (DXRX) Discussions and Chat

Diaceutics Forums and Chat

Date Time Title Posts
14/2/202413:11DIACEUTICS SETS OUT STALL TO DOMINATE PRECISION MEDICINE TEST MARKET125

Add a New Thread

Diaceutics (DXRX) Most Recent Trades

Trade Time Trade Price Trade Size Trade Value Trade Type
16:14:4496.002221.12O
11:00:3795.968,7908,434.88O
10:31:0096.00222213.12O
10:00:4395.961,9441,865.46O
09:00:0397.007572.75UT

Diaceutics (DXRX) Top Chat Posts

Top Posts
Posted at 28/2/2024 08:20 by Diaceutics Daily Update
Diaceutics Plc is listed in the Testing Laboratories sector of the London Stock Exchange with ticker DXRX. The last closing price for Diaceutics was 97p.
Diaceutics currently has 84,472,431 shares in issue. The market capitalisation of Diaceutics is £81,093,534.
Diaceutics has a price to earnings ratio (PE ratio) of 111.63.
This morning DXRX shares opened at 96.50p
Posted at 25/7/2023 18:42 by 1c3479z
wouldn't put it as strongly as that; there's many a company long expected to be taken over yet which has never received a bid...
DXRX value might be in the data lake they hold except ?this is the property of the large pharmas so their real value could be in their client list and lab connections.
Posted at 22/6/2023 06:47 by chrisdgb
If it stays at this price, a takeover in the next year looks inevitable........
Posted at 21/4/2023 09:25 by tomps2
Diaceutics (DXRX) Full Year 2022 Results presentation - April 2023

Diaceutics CFO, Nick Roberts & CIO Ryan Keeling present full year results for the period ended 31 December 2022, which shows a strong trading performance with continued momentum driving strategic investment into 2023.

Watch the video here:

Listen to the podcast here:
Posted at 17/4/2023 10:33 by kalai1
Diaceutics PLC posted Finals for FY22 this morning titled "Strong trading performance with continued momentum driving strategic investment into 2023." Revenues increased 40% to £19.5 million, a 26% increase on a constant currency basis and materially ahead of initial expectations.Gross profit increased by 37% to £16.7 million, EBITDA was £3.6 million (2021: £2.3 million) with an EBITDA margin of 18%, slightly ahead of the prior year (2021: 17%). The outook is solid with order books up to £16.9 million, while the balance sheet is also strong with cash and cash equivalents of £19.8 million. Valuation looks a little unhelpful with PS ratio at around 5.5x, the share price also lacks positive momentum. DXRX has a solid track record of topline growth but is a share to monitor for the time being...

...from WealthOraacle
Posted at 27/7/2022 18:17 by hedgehog 100
"DIACEUTICS TO BECOME FOURTH NORTHERN IRISH COMPANY LISTED ON LONDON STOCK EXCHANGE

RONAN LEONARD MARCH 18, 2019

Diaceutics plc, a revenue-generating, and profitable diagnostics data analytics and implementation services company which services the global pharmaceutical industry, today announces that it is seeking a listing on the AIM Market of the London Stock Exchange. This will make Diaceutics the fourth Northern Irish company currently listed on the London Stock Exchange. The company is expected to have a market capitalisation on admission of approximately £53M. ..."




Rockpool Acquisitions (ROC) is a main-listed cash shell, which may be of interest to investors seeking other Northern Ireland investments to DXRX:-

"A listed acquisition vehicle seeking opportunities in Northern Ireland.

Northern Ireland has a good availability of high quality, often internationally-focused, companies. Despite having an estimated 70,000 registered businesses, there are only two other publicly-listed companies predominantly based in Northern Ireland and Rockpool believes that more Northern Ireland businesses could benefit from the ability to tap into deeper pools of capital which access to the public markets provides.

With extensive knowledge and experience of the Northern Ireland market, the directors are seeking to identify and acquire a highly ambitious, Northern Ireland-based company that is focused on significant growth, and provide it with that access, helping that company meet its aspirations and full potential. Target companies will have a valuation of up to £20m."




Rockpool Acquisitions (ROC) 4.75p Market cap. £604K.




ROC has about £950K. cash, and extremely low cashburn.

ROC's large discount at the moment to its cash, despite this extremely low cashburn, looks like a temporary discrepancy - and one that is gradually being addressed by ROC's share price rise, as the market wakes up to the opportunity.
Posted at 23/3/2022 08:37 by tomps2
Diaceutics (DXRX) full year 2021 results presentation March 2022


Diaceutics Founder & CEO, Peter Keeling, and CFO, Nick Roberts, present full year results for the period ended 31 December 2021. These results show revenue increased 10% to £13.9m. Gross profit increased 13.4% to £10.7m. With a gross margin of 77%. Adjusted EBITDA was £2.3m and profit before tax £0.5m. Net cash £19.7m.


Watch the video here:

Or listen to the podcast here:
Posted at 16/2/2022 18:07 by km18
...from last month...

Company overview:Diaceutics plc is involved in the provision of data analytics to assist pharmaceutical companies worldwide. Diaceutics is known for its robust pipeline development and concise diagnostic testing data conducted from a network of laboratories to find partners for collaboration on accurate medicine diagnostics.  This plausible initiative enabled the firm to obtain a competitive advantage and thereby was incorporated into the firm’s financials prospects, where revenue grew 17% and EBITDA leapt to £2.1m from £0.5m. Despite the favourable corporate news, the firm is expected to experience an additional 29% growth in revenue during 2022, illustrated by its CAGR rate....from WealthOracleAM
Posted at 17/9/2021 07:15 by tomps2
DXRX interim results presentation September 2021

Diaceutics CEO, Peter Keeling and CFO, Philip White present the half year results for the period ending 30th June 2021.

Watch the video here:

Or listen to the podcast here:
Posted at 14/9/2021 12:32 by capitalaccessgroup
Diaceutics Initiation Note

We have today initiated coverage of Diaceutics plc, which has developed the world’s first all-parties marketplace platform (“DXRX”) that allows its clients, pharmaceutical companies, to review and connect with the laboratories and diagnostic companies needed to aid in the development, roll out, & uptake of the diagnostics which enable patient selection for the Pharmas’ Precision Medicines. Key to the investment case is that DXRX is now a heavily invested and scalable platform, with 70%-80% incremental gross margins and a relatively fixed cost base, operating in a high growth industry. It should therefore benefit from material operating leverage as top line growth returns post-pandemic, and we expect margins to grow significantly. You can read it here, or contact us to discuss it with the analyst.

You can find the full research here:
capitalaccessgroup.co.uk/research-portal#/portal/capital-access-group
Posted at 06/9/2021 22:33 by sharesoc
We are hosting a webinar with Diaceutics PLC (DXRX) on the 22nd September, which may be of interest to shareholders or potential investors. Peter Keeling (CEO & Founder) and Philip White (CFO) will provide the latest updates:
Diaceutics share price data is direct from the London Stock Exchange

Your Recent History

Delayed Upgrade Clock

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

Support: +44 (0) 203 8794 460 | support@advfn.com